Compared with anti-PD-L1 or anti-VEGF monotherapy, treatment with anti-PD-L1 plus anti-VEGF inhibition significantly improved PFS and OS in a mouse model of SCLC (31). The gene discussed is VEGFA; the disease is small cell lung carcinoma.